• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

托珠单抗治疗巨细胞动脉炎:惊人的疗效。

Tocilizumab for giant cell arteritis: an amazing result.

机构信息

Division of Rheumatology, Department of Internal Medicine, Hacettepe University Hospital, Sihhiye, 06100, Ankara, Turkey,

出版信息

Rheumatol Int. 2013 Nov;33(11):2961-2. doi: 10.1007/s00296-012-2516-z. Epub 2012 Sep 11.

DOI:10.1007/s00296-012-2516-z
PMID:22965672
Abstract

Giant cell arteritis (GCA), previously Horton's disease, is a systemic vasculitis affecting the middle-sized or large arteries in patients older than 50 years of age. The mainstay of the treatment of GCA is glucocorticoid therapy. Herein, we present a case with giant cell arteritis resistant to oral and intravenous steroid, intravenous cyclophosphamide and mycophenolate mofetil, but successfully treated with tocilizumab.

摘要

巨细胞动脉炎(GCA),以前称为 Horton 病,是一种系统性血管炎,影响 50 岁以上患者的中等或大动脉。GCA 的主要治疗方法是糖皮质激素治疗。在此,我们报告了一例对口服和静脉类固醇、静脉环磷酰胺和霉酚酸酯耐药的巨细胞动脉炎,但成功地用托珠单抗治疗。

相似文献

1
Tocilizumab for giant cell arteritis: an amazing result.托珠单抗治疗巨细胞动脉炎:惊人的疗效。
Rheumatol Int. 2013 Nov;33(11):2961-2. doi: 10.1007/s00296-012-2516-z. Epub 2012 Sep 11.
2
Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.托珠单抗治疗巨细胞动脉炎:34例患者的多中心回顾性研究
J Rheumatol. 2016 Aug;43(8):1547-52. doi: 10.3899/jrheum.151252. Epub 2016 May 15.
3
Tocilizumab in the treatment of giant cell arteritis.托珠单抗治疗巨细胞动脉炎。
Immunotherapy. 2018 Mar 1;10(6):465-472. doi: 10.2217/imt-2017-0182. Epub 2018 Mar 5.
4
Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.托珠单抗治疗巨细胞动脉炎。临床实践中 134 例患者的观察性、开放性、多中心研究。
Semin Arthritis Rheum. 2019 Aug;49(1):126-135. doi: 10.1016/j.semarthrit.2019.01.003. Epub 2019 Jan 5.
5
A severe cerebral infarction associated with giant cell arteritis, which developed during tocilizumab therapy and was successfully treated with intravenous cyclophosphamide.一例与巨细胞动脉炎相关的严重脑梗死,在托珠单抗治疗期间发生,并通过静脉注射环磷酰胺成功治疗。
Mod Rheumatol Case Rep. 2023 Jun 19;7(2):453-457. doi: 10.1093/mrcr/rxad009.
6
Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.是否存在糖皮质激素抵抗性大血管血管炎(巨细胞动脉炎和 Takayasu 动脉炎),如何实现缓解?文献综述。
Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S114-29. Epub 2012 May 11.
7
[Treatment of giant cell arteritis: what is in the pipeline?].[巨细胞动脉炎的治疗:有哪些正在研发中的药物?]
Z Rheumatol. 2020 Aug;79(6):516-522. doi: 10.1007/s00393-020-00808-0.
8
The role of biologics in the treatment of giant cell arteritis.生物制剂在巨细胞动脉炎治疗中的作用。
Expert Opin Biol Ther. 2019 Jan;19(1):65-72. doi: 10.1080/14712598.2019.1556256. Epub 2018 Dec 12.
9
Efficacy of tocilizumab in refractory giant cell arteritis.托珠单抗治疗难治性巨细胞动脉炎的疗效。
Joint Bone Spine. 2012 May;79(3):317-8. doi: 10.1016/j.jbspin.2011.11.008. Epub 2012 Jan 27.
10
Giant Cell Arteritis: 2018 Review.巨细胞动脉炎:2018年综述
Mo Med. 2018 Sep-Oct;115(5):468-470.

引用本文的文献

1
Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants?巨细胞动脉炎和风湿性多肌痛靶向治疗时代的生物标志物:是否有可能替代急性期反应物?
Front Immunol. 2023 Jun 15;14:1202160. doi: 10.3389/fimmu.2023.1202160. eCollection 2023.
2
Rapid visual recovery following intravenous tocilizumab in glucocorticoid resistant refractory giant cell arteritis.静脉注射托珠单抗治疗糖皮质激素抵抗性难治性巨细胞动脉炎后视力迅速恢复
BMJ Case Rep. 2019 Oct 5;12(10):e229236. doi: 10.1136/bcr-2019-229236.
3
Update on the management of giant cell arteritis.

本文引用的文献

1
Biologic treatment of large-vessel vasculitides.大血管血管炎的生物治疗。
Curr Opin Rheumatol. 2012 Jan;24(1):31-7. doi: 10.1097/BOR.0b013e32834dc392.
2
Tocilizumab: a novel therapy for patients with large-vessel vasculitis.托珠单抗:一种治疗大血管血管炎患者的新疗法。
Rheumatology (Oxford). 2012 Jan;51(1):151-6. doi: 10.1093/rheumatology/ker296. Epub 2011 Nov 10.
3
Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis.抗白细胞介素6受体疗法作为巨细胞动脉炎的挽救治疗
巨细胞动脉炎的治疗进展
Ther Adv Chronic Dis. 2017 Apr;8(4-5):69-79. doi: 10.1177/2040622317700089. Epub 2017 Mar 28.
4
Biologic Therapy for the Treatment of Giant Cell Arteritis.治疗巨细胞动脉炎的生物疗法。
Neuroophthalmology. 2014 Apr 2;38(3):107-112. doi: 10.3109/01658107.2014.883635. eCollection 2014.
5
Tocilizumab: a new therapy for large vessel vasculitis.托珠单抗:一种治疗大血管血管炎的新疗法。
Clin Exp Med. 2014 Nov;14(4):355-60. doi: 10.1007/s10238-013-0254-5. Epub 2013 Aug 15.
6
Design of the tocilizumab in giant cell arteritis trial.托珠单抗治疗巨细胞动脉炎试验的设计
Int J Rheumatol. 2013;2013:912562. doi: 10.1155/2013/912562. Epub 2013 Apr 7.
Ann Rheum Dis. 2011 Oct;70(10):1874-5. doi: 10.1136/ard.2010.149351. Epub 2011 Apr 24.
4
New therapies in the management of rheumatoid arthritis.类风湿关节炎治疗的新疗法。
Curr Opin Rheumatol. 2011 May;23(3):245-51. doi: 10.1097/BOR.0b013e3283454124.
5
Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series.白介素 6 阻断治疗大血管血管炎的快速缓解:病例系列研究。
Swiss Med Wkly. 2011 Jan 17;141:w13156. doi: 10.4414/smw.2011.13156. eCollection 2011.
6
Giant cell arteritis: an updated review.巨细胞动脉炎:最新综述。
Acta Ophthalmol. 2009 Feb;87(1):13-32. doi: 10.1111/j.1755-3768.2008.01314.x. Epub 2008 Oct 7.
7
Polymyalgia rheumatica and giant-cell arteritis.风湿性多肌痛和巨细胞动脉炎。
Lancet. 2008 Jul 19;372(9634):234-45. doi: 10.1016/S0140-6736(08)61077-6.
8
Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.辅助性甲氨蝶呤治疗巨细胞动脉炎:一项个体患者数据荟萃分析。
Arthritis Rheum. 2007 Aug;56(8):2789-97. doi: 10.1002/art.22754.
9
Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment.巨细胞动脉炎导致的永久性视力丧失和脑血管意外:预测因素及治疗反应
Arthritis Rheum. 1998 Aug;41(8):1497-504. doi: 10.1002/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z.